Current Hypertension Reports

, Volume 12, Issue 4, pp 258–266

Do the Blood Pressure Effects of Nonsteroidal Antiinflammatory Drugs Influence Cardiovascular Morbidity and Mortality?



There are many theories about why selective inhibitors of the second isoform of cyclooxygenase (COX-2) increase cardiovascular risk. Although torcetrapib raises blood pressure and cardiovascular risk, it has been difficult to prove such a link for COX-2 inhibitors in randomized clinical trials. This review shows a significant correlation in placebo-controlled trials between the five agents’ elevations in blood pressures and their rate ratios for cardiovascular events. A larger body of evidence arises from randomized clinical trial comparisons of selective versus nonselective inhibitors of COX-2, but these results are heterogeneous for naproxen versus other traditional agents. The best current trial evidence comes from the centrally adjudicated placebo-controlled trials of celecoxib for colonic polyps: If the blood pressure did not rise at 1 or 3 years after randomization, cardiovascular risk did not significantly increase. Many more data will become available in 2013, after the only prospective clinical trial involving cardiovascular end points is completed.


Meta-analysis Celecoxib Rofecoxib Valdecoxib Etoricoxib Parecoxib Lumiracoxib COX-2 inhibitors Incident hypertension Composite cardiovascular end point 


Recently published papers of interest have been highlighted as: • Of importance •• Of major importance

  1. 1.
    McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA 2006, 296:1633–1644.CrossRefPubMedGoogle Scholar
  2. 2.
    Chan AT, Manson JE, Albert CM, et al.: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006, 113:1578–1587.CrossRefPubMedGoogle Scholar
  3. 3.
    Antman EM, Bennett JS, Daugherty A, et al.: Use of nonsteroidal antiinflammatory drugs: an update for clinicians. A Scientific Statement from the American Heart Association. Circulation 2007, 115:1634–1642.CrossRefPubMedGoogle Scholar
  4. 4.
    FitzGerald GA: Coxibs and cardiovascular disease. N Engl J Med 2004, 351:1709–1711.CrossRefPubMedGoogle Scholar
  5. 5.
    McAdam BF, Catella-Lawson F, Mardini IA, et al.: Systematic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Nat Acad Sci U S A 1999, 96:272–277.CrossRefGoogle Scholar
  6. 6.
    Cheng Y, Austin SC, Rocca B, et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296:539–541.CrossRefPubMedGoogle Scholar
  7. 7.
    Arehart E, Stitham J, Asselbergs FW, et al.: Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res 2008, 102:986–993.CrossRefPubMedGoogle Scholar
  8. 8.
    Grosser T, Fries S, FitzGerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibitors: therapeutic challenges and opportunities. J Clin Invest 2006, 116:4–15.CrossRefPubMedGoogle Scholar
  9. 9.
    Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520–1528.CrossRefPubMedGoogle Scholar
  10. 10.
    Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954–959.CrossRefPubMedGoogle Scholar
  11. 11.
    Cannon CP, Curtis SP, FitzGerald GA, et al.: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006, 368:1771–1781.CrossRefPubMedGoogle Scholar
  12. 12.
    • Garcia Rodriguez LA, Tacconelli S, Patrignani P: Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008, 52:1628–1636. Data from a population-based cohort in Italy showed increased risk of myocardial infarction in users of NSAIDs, especially diclofenac and rofecoxib; the authors proposed a testable model for such compounds that may increase cardiovascular risk. Google Scholar
  13. 13.
    Padol IT, Hunt RH: Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response, resulting in atheromatous plaque instability: an evidence-based interpretation. Rheumatology (Oxford) 2010, 49:837–843.CrossRefGoogle Scholar
  14. 14.
    Mitchell JA, Lucas R, Vojnovic I, et al.: Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J 2006, 20:2468–2475.CrossRefPubMedGoogle Scholar
  15. 15.
    Marwali MR, Mehta JL: COX-2 inhibitors and cardiovascular risk: inferences based on biology and clinical studies. Thromb Haemost 2006, 96:401–406.PubMedGoogle Scholar
  16. 16.
    Zhang J, Ding EL, Song Y: Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006, 296:1619–1632.CrossRefPubMedGoogle Scholar
  17. 17.
    •• Chan CC, Reid CM, Aw TJ, et al.: Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009, 27:2332–2341. This update to these authors’ prior meta-analysis on the same topic [18] is the most comprehensive and up-to-date meta-analysis of currently available data. The authors’ discussion of the challenges in collecting and interpreting these data is especially helpful and important.Google Scholar
  18. 18.
    Aw TJ, Haas SJ, Liew D, Krum H: Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005, 165:490–496.CrossRefPubMedGoogle Scholar
  19. 19.
    Aneja A, Farkouh ME: Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? Ther Adv in Cardiovasc Dis 2008, 2:53–66.CrossRefGoogle Scholar
  20. 20.
    Grover SA, Coupal L, Zowall H: Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: What are the benefits of avoiding blood pressure destabilization? Hypertension 2005, 45:92–97.PubMedGoogle Scholar
  21. 21.
    •• Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2107–2122. An excellent recent example of how an “off-target” elevation in blood pressure could have been responsible for an increase in cardiovascular risk when the drug itself was effective in treating dyslipidemia and was intended to reduce cardiovascular risk.Google Scholar
  22. 22.
    Dullaart RP, Muller Kobold AC, van Tol A: Torcetrapib and coronary events [letter]. N Engl J Med 2008, 358:1862–1864.Google Scholar
  23. 23.
    Forrest MJ, Bloomfield D, Briscoe RJ, et al.: Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008, 154:1465–1473.CrossRefPubMedGoogle Scholar
  24. 24.
    Hu X, Dietz JD, Xia C, et al.: Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 2009, 150:2211–2219.CrossRefPubMedGoogle Scholar
  25. 25.
    Aw TJ, Liew D, Tofler GH, et al.: Can the blood pressure effects of COX-2 selective inhibitors be explained by the changes in plasma aldosterone levels? J Hypertens 2006, 24:1979–1984.CrossRefPubMedGoogle Scholar
  26. 26.
    Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153:477–484.CrossRefPubMedGoogle Scholar
  27. 27.
    Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289–300.PubMedGoogle Scholar
  28. 28.
    Whelton A, Fort JG, Puma JA, et al.: SUCCESS VI Study Group: Cyclooxygenase-2–specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001, 8:85–95.CrossRefPubMedGoogle Scholar
  29. 29.
    Whelton A, White WB, Bello AE, et al.; SUCCESS-VII Investigators: Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥ 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002, 90:959–963.CrossRefPubMedGoogle Scholar
  30. 30.
    • Wang J, Mullins CD, Mamdani M, et al.: New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study. Ann Pharmacol 2007, 41:937–943. This good example of a typical “comparative effectiveness” study of pharmacy records showed little difference in risk of a new prescription for an antihypertensive agent in people previously treated with celecoxib or a nonselective NSAID.Google Scholar
  31. 31.
    Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247–1255.CrossRefPubMedGoogle Scholar
  32. 32.
    • Chen LC, Ashcroft DM: Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised clinical trials. Pharmacoepidemiol Drug Saf 2007, 16:762–772. In fixed-effects models, the risk of myocardial infarction was higher for five COX-2 selective agents compared with placebo or nonselective NSAIDs, with rofecoxib having the highest risk, compared with naproxen, and valdecoxib having a lower risk, compared with diclofenac.Google Scholar
  33. 33.
    Kearney PM, Baigent C, Godwin J, et al.: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherosclerosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302–1308.CrossRefPubMedGoogle Scholar
  34. 34.
    Weir MR, Sperling RS, Reicin A, Gertz BJ: Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003, 146:591–604.CrossRefPubMedGoogle Scholar
  35. 35.
    Jüni P, Nartey L, Reichenbach S, et al.: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004, 364:2021–2029.CrossRefPubMedGoogle Scholar
  36. 36.
    • Ross JS, Madigan D, Hill KP, et al.: Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons from postmarket pharmaceutical safety vigilance. Arch Intern Med 2009, 169:1976–1985. This update of an earlier publication [46], using all data that were made public after the FDA Advisory Committee Hearings, showed that, in cumulative meta-analyses, the risk of cardiovascular events was significantly higher than placebo well before the conclusion of the APPROVe trial.Google Scholar
  37. 37.
    White WB, West CR, Borer JS, et al.: Risk of cardiovascular events in patients receiving celecoxib: A meta-analysis of randomized clinical trials. Am J Cardiol 2007, 99:91–98.CrossRefPubMedGoogle Scholar
  38. 38.
    White WB, Faich G, Borer JS, Makuch RW: Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor, celecoxib. Am J Cardiol 2003, 92:411–418.CrossRefPubMedGoogle Scholar
  39. 39.
    Curtis SP, Ko AT, Bolognese JA, et al.: Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective inhibitor, etoricoxib. Curr Med Res Opin 2006, 22:2365–2374.CrossRefPubMedGoogle Scholar
  40. 40.
    White WB, Strand V, Roberts R, Whelton A: Effects of the cyclooxygenase-2 specific inhibitor, valdecoxib versus nonsteroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Therap 2004, 11:244–250.CrossRefGoogle Scholar
  41. 41.
    Aldington S, Shirtcliffe P, Weatherall M, Beasley R: Increased risk of cardiovascular events with parecoxib/valdecoxib: A systematic review and meta-analysis. N Z Med J 2005, 118:U1755.PubMedGoogle Scholar
  42. 42.
    Matchaba P, Gitton X, Krammer G, et al.: Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized trials > or = 1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin Ther 2005, 27:1196–1214.CrossRefPubMedGoogle Scholar
  43. 43.
    Lumley T: Network meta-analysis for indirect treatment comparisons. Stat Med 2002, 21:2313–2324.CrossRefPubMedGoogle Scholar
  44. 44.
    Lunn DJ, Thomas A, Best N, Spiegelhalter D: WinBUGS—A Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comp 2000, 10:325–337.CrossRefGoogle Scholar
  45. 45.
    Elliott WJ, Hewkin AC, Kupfer S, et al: A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. J Clin Hypertens (Greenwich) 2005, 7:654–663.CrossRefGoogle Scholar
  46. 46.
    Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092–1102.CrossRefPubMedGoogle Scholar
  47. 47.
    Solomon SD, Pfeffer MA, McMurray JJV, et al.: Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006, 114:1028–1035.CrossRefPubMedGoogle Scholar
  48. 48.
    Antiplatelet Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002, 324:71–86.CrossRefGoogle Scholar
  49. 49.
    • Becker MC, Wang TH, Wisniewski L, et al.: Rationale, design, and governance of the Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J 2009, 157:606–612. This “definitive” randomized clinical trial should have sufficient statistical power to properly test the hypothesis that cardiovascular risk associated with celecoxib is not inferior to that of ibuprofen or naproxen in arthritis patients. Results are expected in 2013.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of PharmacologyPacific Northwest University of Health SciencesYakimaUSA

Personalised recommendations